ctl-002,nivolumab
bms,catal ym
['ctl-002', 'nivo', 'solid tumor', 'nivolumab']
dr ignacio melero:
the final results of first-in-human clinical trial of the gdf-15 neutralizing antibody ctl-002 in combination with nivolumab in subjects with solid tumors relapsed/refractory to prior anti-pd1/pd-l1 treatment showed good safety and clinical responses. #esmo2022
Flagship #OpenAccess medical journal from @BioMedCentral. Publishes research articles & reviews in all areas of research & practice in #medicine & #globalhealth